Dr. Baomin Xin has nearly 20 years of experiences in the pharmaceutical industry, serving executive and leadership roles in both the US and China. Before joining Medicilon, Dr. Xin has worked at major pharmaceutical companies and CROs, including Bristol-Myers Squibb (BMS), DuPont Pharmaceutical Company (DPC), and WuXi AppTec. As a Principal Scientist leading the Bioanalytical Research Department at BMS Hopewell site, Dr. Xin has made significant contributions to many discovery programs within the company, especially in the Cardiovascular and Metabolic Disease therapeutic areas, successfully bringing several new medicines to the market including Eliquis (Apixaban).
Dr. Xin has also worked at WuXi AppTec in China, leading the Bioanalytical Services Department (LC-MS) to provide regulated (GLP/GCP) bioanalysis to support new drug development projects from pharmaceutical companies worldwide, as well as BE projects for the generic drug sector. His team has successfully passed over 20 CFDA inspections and a US FDA inspection with no 483s.
Dr. Xin obtained his PhD under Professor Milton L Lee at Brigham Young University (BYU). He is currently leading the DMPK and Bioanalytical Services department at Medicilon.
Shanghai Medicilon Inc.